I wildly agree with you Trip. And what I think I see playing out with a possible partnership, or buyout, is PharmaCyte preparing (just in case) for an uplist.
I've read where a reverse split normally coincides with an offering to a third-party.
4+ million dollars and no debt makes for a decent balance sheet, along with a reverse split to get the capital structure in line, all makes sense.
Make things right for the suiter. :) :) :)
Go PharmaCyte!!!